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Results
.
This meta-analysis demonstrates a significant
increase in the rate of vascular occlusive events
associated with the use of dasatinib, nilotinib and
ponatinib compared to imatinib. However, even if
no statistical significance was found for
bosutinib, a trend was also depicted. Dasatinib,
nilotinib and ponatinib should be associated with
frequent cardiovascular monitoring and an
intensive support of comorbidities. Ponatinib
should be reserved for patients with advanced
disease or patients with the T315I mutation, or
when others treatments cannot be used. Further
dose-ranging studies are required to define the
dose regimen of each BCR-ABL TKI that will
provide the best benefit-risk profile. Finally,
monitoring the response at the individual level is
of utmost importance to reduce the risk of
vascular occlusive events while keeping the
benefit in term of MMR.
Conclusions
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Discussion
Dasatinib, nilotinib and ponatinib are associated with a higher rate of vascular occlusive events compared to imatinib. Even
if the results are not statistically significant with bosutinib, there is a trend toward an increased risk of vascular occlusive
events. However, little is known about the exact incidence of vascular occlusive events in long-term TKI-treated patients
with CML and about factors predisposing for vascular occlusive events development. Several case-reports, retrospective
and prospective studies analysed the correlations between pre-existing risk factors and arterial occlusive disease
occurrence and demonstrated that arterial occlusive events develop predominantly in patients with one or more risk factors
(hypertension, diabetes, hyperlipidaemia, obesity, smoking and prior vascular disease) prior to TKI treatment (i.e. nilotinib
and ponatinib). The MMR at one year is achieved by almost twice as many patients when using the novel generation TKI.
However, the improvement of overall survival is not achieved at this data lock point, i.e. 1 year.
The cardiovascular risk is likely to be dose-related. However, the currently available data on the dose-efficacy and dose-
toxicity relationship are not sufficient to make a formal recommendation on dose reduction, and there is a risk that lower
doses might have reduced efficacy. Safety and efficacy data concerning dose reduction following major cytogenetic
response (MCyR) have been included in the EU-SmPC of Iclusig® (ponatinib). A dose-ranging study in patients with
chronic phase CML is currently recruiting to determine the optimal starting dose of ponatinib and characterise the safety
and efficacy of ponatinib following dose reduction after achieving MCyR (OPTIC trial - NCT02467270). Such risk
minimization measures are not yet implemented with the other TKI of interest, i.e. dasatinib and nilotinib, with whom the
risk of vascular occlusive events is clearly identified.
BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: a 
systematic review and meta-analysis on the risk of cardiovascular 
events, major molecular response and overall survival
ObjectivesBackground
A high incidence of arterial events including peripheral
artery occlusive diseases (PAOD) has been observed with
ponatinib during the clinical development.1 This brought the
Food and Drug Administration (FDA) to include a boxed
warning indicated that 8% of patients treated by ponatinib
experienced serious arterial thrombosis.
Serious cases of PAOD were also reported in CML patients
treated with nilotinib in clinical trials and in post-marketing
experience.2 However, these reports were not considered
conclusive, due to the small number of patients and the
retrospective design.3 To date, no signal of increased risk of
vascular thrombosis and embolism was found in clinical
trials with imatinib and dasatinib. However, some cases
were reported post-marketing.
• To assess the risk of vascular occlusive events
with novel generation BCR-ABL TKI (i.e.
bosutinib, dasatinib, nilotinib and ponatinib) in
CML patients compared with imatinib.
• Stratifications by BCR-ABL TKI are performed to
provide product specific risk assessment.
• Data on the overall survival and the MMR were
also extracted to provide global benefit-risk
evaluation.
Methods
Literature search
• The research of randomized clinical trials was performed for
bosutinib, dasatinib, nilotinib and ponatinib.
• Systematic trial research from inception until November 21,
2014
• Only randomized clinical trials that compared a novel
generation of BCR-ABL TKI versus standard of care (i.e.
imatinib) were included.
• Restriction to the subgroup analysis of clinical trials that
involved leukemic patients
Statistical analysis:
• Fixed-effect model
• Odds ratio using the Peto method
• One-way sensitivity analysis for robustness
• Heterogeneity: Cochran’s Q statistic and I2
Results
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Figure 2: Forest plot of the included studies for the risk of 
myocardial infarction, major bleedings and all-cause mortality
(Fixed effect model analyses)
Vascular occlusive events
Overall survival
Major molecular response
Group by
Subgroup within study
Study name Treatment Comparison Statistics for each study Peto odds ratio and 95% CI
Peto Lower Upper Relative 
odds ratio limit limit p-Value weight
bosutinib NCT00574873 - BELA bosutinib imatinib 2,77 0,39 19,77 0,310 100,00
bosutinib 2,77 0,39 19,77 0,310
dasatinib NCT00070499 dasatinib imatinib 7,39 0,15 372,38 0,317 7,37
dasatinib NCT00103844 - START-R dasatinib imatinib 4,46 0,23 86,51 0,323 12,88
dasatinib NCT00320190 dasatinib imatinib 0,09 0,00 4,61 0,227 7,11
dasatinib NCT00481247- DASISION dasatinib imatinib 4,86 1,30 18,12 0,019 65,29
dasatinib NCT00852566 - NordCML006 dasatinib imatinib 8,09 0,16 409,34 0,296 7,35
dasatinib 3,86 1,33 11,18 0,013
nilotinib NCT00471497 - ENESTnd nilotinib imatinib 3,31 1,95 5,61 0,000 89,00
nilotinib NCT00760877 - ENESTcmr nilotinib imatinib 4,45 0,99 20,02 0,052 11,00
nilotinib 3,42 2,07 5,63 0,000
ponatinib NCT01650805 - EPIC ponatinib imatinib 3,47 1,23 9,78 0,019 100,00
ponatinib 3,47 1,23 9,78 0,019
Overall 3,45 2,30 5,18 0,000
0,01 0,1 1 10 100
Imatinib New generation TKI
A. Vascular occlusive events
Group by
Subgroup within study
Study name Treatment Comparison Statistics for each study Peto odds ratio and 95% CI
Peto Lower Upper Relative 
odds ratio limit limit p-Value weight
bosutinib NCT00574873- BELA bosutinib imatinib 2,38 0,82 6,89 0,109 100,00
bosutinib 2,38 0,82 6,89 0,109
dasatinib NCT00070499 dasatinib imatinib 0,14 0,00 6,82 0,317 8,24
dasatinib NCT00481247 - DASISION dasatinib imatinib 0,36 0,11 1,24 0,105 83,53
dasatinib NCT00852566 - NordCML006 dasatinib imatinib 6,80 0,13 343,88 0,338 8,23
dasatinib 0,42 0,14 1,31 0,135
nilotinib NCT00471497- ENESTnd nilotinib imatinib 2,12 0,48 9,25 0,319 87,60
nilotinib NCT00760877- ENESTcmr nilotinib imatinib 0,14 0,00 6,89 0,320 12,40
nilotinib 1,51 0,38 5,99 0,561
ponatinib NCT01650805- EPIC ponatinib imatinib 2,00 0,21 19,33 0,551 100,00
ponatinib 2,00 0,21 19,33 0,551
Overall 1,20 0,63 2,29 0,576
0,01 0,1 1 10 100
Imatinib New generation TKI
B. Overall survival
Group by
Subgroup within study
Study name Treatment Comparison Statistics for each study Peto odds ratio and 95% CI
Peto Lower Upper Relative 
odds ratio limit limit p-Value weight
bosutinib NCT00574873 - BELA bosutinib imatinib 1,86 1,29 2,70 0,001 100,00
bosutinib 1,86 1,29 2,70 0,001
dasatinib NCT00070499 dasatinib imatinib 1,84 1,10 3,06 0,019 27,52
dasatinib NCT00103844 - START-R dasatinib imatinib 2,50 1,12 5,58 0,026 11,05
dasatinib NCT00481247 - DASISION dasatinib imatinib 2,15 1,51 3,07 0,000 56,34
dasatinib NCT00852566 - NordCML006 dasatinib imatinib 4,33 1,32 14,13 0,015 5,10
dasatinib 2,17 1,66 2,83 0,000
nilotinib NCT01400074 - RE-NICE nilotinib imatinib 1,14 0,33 3,94 0,837 5,10
nilotinib NCT00471497 - ENESTnd nilotinib imatinib 2,49 1,85 3,34 0,000 88,98
nilotinib NCT00760877 - ENESTcmr nilotinib imatinib 3,77 1,19 11,91 0,024 5,92
nilotinib 2,45 1,85 3,24 0,000
ponatinib NCT01650805 - EPIC ponatinib imatinib 4,95 0,97 25,19 0,054 100,00
ponatinib 4,95 0,97 25,19 0,054
Overall 2,22 1,87 2,63 0,000
0,01 0,1 1 10 100
Imatinib New generation TKI
C. Major molecular response
Figure 1: PRISMA (Preferred Reporting Items for Systematic 
Reviews and Meta-Analysis) flow diagram of study selection.
Figure 3: One-way sensitivity analysis of the risk of vascular
occlusive events in the leukemic population stratified by treatment
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